Pancreatic Cancer

Pancreatic Cancer

A Phase II multicenter clinical trial using an anti-angiogenic drug combination designed for the treatment of cancer. The goal was to recruit 99 patients suffering from pancreatic cancer across 10 sites.

Study challenges

The recruitment was a challenge due to rigorous inclusion criteria. The indication had a number of other competing clinical trials at many of the sites. But the main challenging criterion was sadly the very low life expectancy of the patients. In addition, the patients had to be “naïve” - before the first chemo treatment - which meant targeting them in the 2 weeks following diagnosis.


After conducting rigorous research, nRollmed had several strategic insights for recruitment: The patients spent a lot of time seeking alternative treatments across the web and were therefore particularly open to enrolling in clinical trials. Also, patients were less limited to geographical location and were willing to travel longer distances for the opportunity to receive potentially life-saving treatment.

Campaign results

nRollmed operated both an online campaign and a call center. 400 leads were gathered by the online campaign, and 25% of the trial’s recruited patients were recruited via nRollmed.